AAV

REGENXBIO (Nasdaq: RGNX) will participate in several investor conferences in September 2025, including events hosted by Wells Fargo, Morgan Stanley, Baird, and H.C. Wainwright. The company will engage in one-on-one meetings and fireside chats to discuss its strategic vision, clinical progress, and the potential of its AAV gene therapies for rare and retinal diseases, including RGX-202 for Duchenne muscular dystrophy and surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy. Webcasts will be available on REGENXBIO’s website.